Ifosfamide in the treatment of head and neck cancer

Oncology

Volumn 65, Issue SUPPL. 2, 2003, Pages 37-43

  Airoldi, M ^a   Cortesina, G ^b   Giordano, C ^b   Pedani, F ^a   Bumma, C ^a  

^a MOLINETTE HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Head and neck cancer; Ifosfamide; Nasopharyngeal carcinoma; Taxol

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; ISOTRETINOIN; MESNA; METHOTREXATE; MITOXANTRONE; PACLITAXEL; PLATINUM;

ADVANCED CANCER; ANAPHYLAXIS; ANOREXIA; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG TOLERANCE; FATIGUE; FEBRILE NEUTROPENIA; FEVER; GRANULOCYTOPENIA; HEAD AND NECK CARCINOMA; HUMAN; HYPERTHERMIA; INFECTION; LEUKOPENIA; METASTASIS; MUCOSA INFLAMMATION; NASOPHARYNX CARCINOMA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; RECURRENT CANCER; SEPSIS; SQUAMOUS CELL CARCINOMA; TOXICITY; TREATMENT OUTCOME; UNDIFFERENTIATED CARCINOMA; VOMITING;

ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; CISPLATIN; CLINICAL TRIALS; HEAD AND NECK NEOPLASMS; HUMANS; IFOSFAMIDE; NASOPHARYNGEAL NEOPLASMS; NEOADJUVANT THERAPY; PACLITAXEL; TREATMENT OUTCOME;

EID: 0242383230     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000073356     Document Type: Conference Paper

References (40)

1. Vokes EE, Weichselbaum RR, Lippman SM, et al: Head and neck cancer. N Engl J Med 1993;328:184-194.
2. Paccagnella A, Orlando A, Marchiori C, et al: Phase III trial of initial chemotherapy in stage III or IV head and neck cancer: A study of the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 1994;86:265-272.
3. Pignon JP, Bourhis J, Domenge C, et al: Chemotherapy added to locoregional treatment for head and neck squamous cell carcinoma. Three meta-analyses of updated individual data. Lancet 2000;355:949-955.
4. Bernier J, van Glabbeke M, Domenge C, et al: Results of the EORTC phase III trial 22931 comparing, postoperatively, radiotherapy to concurrent chemoradiotherapy with high-dose cisplatin in locally advanced head and neck carcinomas. Eur J Cancer 2001;37(suppl 6):267.
5. Cooper JS, Pajak TF, Forastiere AA, et al: Postoperative concurrent radiochemotherapy in high-risk SCCA of the head and neck: Initial report of RTOG 9501/Intergroup phase III trial. Proc Am Soc Clin Oncol 2002;21:226.
6. Huber MH, Lippman SM, Benner SE, et al: A phase II study of ifosfamide in recurrent squamous cell carcinoma of the head and neck. Am J Clin Oncol 1996;19:379-383.
7. Martin M, Diaz-Rubio E, Gonzales Larriba JL, et al: Ifosfamide in advanced epidermoid head and neck cancer. Cancer Chemother Pharmacol 1993;31:340-342.
8. Buesa JM, Fernandez R, Esteban E, et al: Phase II trial of ifosfamide in recurrent and metastatic head and neck cancer. Ann Oncol 1991;2:151-152.
9. Cervellino JC, Araujo CE, Pirisi C, et al: Ifosfamide and mesna for the treatment of advanced squamous cell head and neck cancer. Oncology 1991;48:89-92.
10. Kish JA, Tapazoglou E, Ensley E, et al: Activity of ifosfamide (NSC-109724) in recurrent head and neck cancer. Proc Am Assoc Cancer Res 1990;31:190.
11. Verweij J, Alexiera-Figresch J, DeBoer MF: Ifosfamide in advanced head and neck cancer. A phase II study of the Rotterdam Cooperative Head and Neck Cancer Study Group. Eur J Cancer Clin Oncol 1988;24:795-796.
12. Sandler A, Saxman S, Bandelay M, et al: Ifos-famide in the treatment of advanced or recurrent squamous cell carcinoma of the head and neck. A phase II Hoosier Oncology Group. Am J Clin Oncol 1998;21:195-197.
13. Pai V, Parikh DM, Mazumdar AT, et al: Phase II study of high-dose ifosfamide as a single agent and in combination with cisplatin in the treatment of advanced and/or recurrent squamous cell carcinoma of the head and neck. Oncology 1993;50:86-91.
14. Gupta V, Arena S, Hilal E, et al: High response rate to cisplatin and ifosfamide/mesna in head and neck cancer. Proc Am Soc Clin Oncol 1994;13:289.
15. Lemke S, Kellman R, Green D, et al: A phase II trial of ifosfamide, cisplatin, oral mesna and ethacrynic acid as an outpatient treatment in advanced squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 1995;14:298.
16. Cervellino JC, Francia A, Araujo C, et al: Treatment of advanced head and neck cancer with ifosfamide/mesna plus carboplatin. Abstr Book III, XVIth Int Cancer Congress, October 30-November 5, 1994, pp 6-10.
17. Bruno M: Ifosfamide/mesna plus carboplatin as neoadjuvant therapy for stage I-III head and neck cancer. Preliminary report; in Banzet P (ed): Cancer Treatment. An Update. Paris, Springer, 1994, pp 263-266.
18. Brucker C, Sieg P: Effect of combined carboplatin and ifosfamide with local hyperthermia on human mouth carcinoma in the animal model. Mund Kiefer Gesichtschir 1999;3(suppl 1):44-46.
19. Sagowski C, Jaehne M, Kehrl W, et al: Tumor oxygenation under combined whole-body hyperthermia and polychemotherapy in a case of recurrent carcinoma of the oral cavity. Eur Arch Otorhinolaryngol 2002;259:27-31.
20. Recchia F, Lalli A, Lombardo M, et al: Ifosfamide, cisplatin and 13-cis-retinoic acid for patients with advanced or recurrent squamous cell carcinoma of the head and neck. A phase I-II study. Cancer 2001;92:814-821.
21. Sanchez-Parra M, Churruca C, Parades A, et al: Phase II clinical trial of cisplatin, 5-fluorouracil and ifosfamide as treatment for advanced locoregional head and neck carcinoma. Am J Clin Oncol 1999;22:6-7.
22. Rixe O, Lacoste JP, Thomas A, et al: Neoadjuvant chemotherapy by CDDP, 5-FU, leucovorin and ifosfamide (PLIF) for advanced head and neck squamous cell carcinoma. Proc Am Soc Clin Oncol 1994;13:290.
23. Domenge C, Schwaab G, Marandas P, et al: Phase II feasibility study of ifosfamide/mesna and methotrexate in recurrent advanced squamous cell head and neck cancer. Proc Am Soc Clin Oncol 1994;13:291.
24. Thurnher D, Kornfehl J, Burian M, et al: Ifosfamide and mitoxantrone in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck. Anticancer Drugs 2001;12:205-208.
25. Forastiere AA, Urba SG: Single-agent paclitaxel and paclitaxel plus ifosfamide in the treatment of head and neck cancer. Semin Oncol 1995;22(suppl 6):24-27.
26. Shin DM, Glisson BS, Khuri FR, et al: Phase II trial of paclitaxel, ifosfamide and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J Clin Oncol 1998;16:1325-1330.
27. Kosmas C, Tsavaris NB, Polyzos A, et al: Phase I study of dose-escalated paclitaxel, ifosfamide and cisplatin (PIC) combination chemotherapy in advanced solid tumors. Br J Cancer 2000;82:300-307.
28. Shin DM, Khuri FR, Glisson BM, et al: Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma. Cancer 2001;91:1316-1323.
29. Shin DM, Glisson BS, Khuri FR, et al: Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. Cancer 2002;95:322-330.
30. Ali H, Al-Sarraf M: Nasopharyngeal cancer. Hematol Oncol Clin North Am 1999;13:837-847.
31. Gabriele AM, Airoldi M, Beatrice F, et al: Combined chemoradiotherapy for stage IV undifferentiated nasopharyngeal carcinoma. Tumori 2000;86:399-402.
32. Orecchia R, Airoldi M, Sola B, et al: Results of chemotherapy plus external re-irradiation in the treatment of locally advanced recurrences of nasopharyngeal carcinoma. Oral Oncol Eur J Cancer 1992;28B:109-111.
33. Airoldi M, Pedani F, Gabriele P, et al: Combined chemotherapy for recurrent and metastatic nasopharyngeal carcinoma. J Chemother 1989;1:272-276.
34. Fandi A, Bachouchi M, Azli N, et al: Long-term disease-free survivors in metastatic undifferentiated carcinoma of the nasopharyngeal type. J Clin Oncol 2000;18:1324-1330.
35. Liu JM, Chan WK, Chi KH, et al: Preliminary report of a phase II trial of ifosfamide in patients with advanced stage nasopharyngeal carcinoma in Taiwan. Proc Am Soc Clin Oncol 1994;13:285.
36. Stein ME, Ruff P, Weaving A, et al: A phase II study of cisplatin/ifosfamide in recurrent/metastatic undifferentiated nasopharyngeal carcinoma among young blacks in Southern Africa. Am J Clin Oncol 1996;19:386-388.
37. Huang HQ, Zhou ZM, Li YH, et al: Preliminary results of ifosfamide and doxorubicin regimen in treatment of patients with recurrent and metastatic nasopharyngeal carcinoma. Ai Zheng 2002;21:409-411.
38. Airoldi M, Pedani F, Marchionatti S, et al: Carboplatin plus taxol is an effective third-line regimen in recurrent undifferentiated nasopharyngeal carcinoma. Tumori 2002;88:273-276.
39. Chua DTT, Kwong DLW, Sham JST, et al: A phase II study of ifosfamide, 5-fluorouracil and leucovorin in patients with recurrent nasopharyngeal carcinoma previously treated with platinum therapy. Eur J Cancer 2002;36:736-741.
40. Airoldi M, De Crescenzo A, Pedani F, et al: Feasibility and long-term results of autologous PBSC transplantation in recurrent undifferentiated nasopharyngeal carcinoma. Head Neck 2001;23:799-803.